BBLG Bone Biologics Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1419554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY28.0%
TTM EPS YoY57.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-47.5%
ROA-44.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets7.5%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $242,569 | $308,747 | $141,597 | $257,197 | $187,808 | $191,608 | $423,576 | $1.10M |
| SG&A expense | $423,771 | $499,359 | $663,457 | $475,908 | $527,466 | $556,467 | $614,910 | $450,367 |
| Operating income | -$666,340 | -$808,106 | -$805,054 | -$733,105 | -$715,274 | -$748,075 | -$1.04M | -$1.55M |
| Net income | -$617,651 | -$773,702 | -$765,988 | -$684,643 | -$666,737 | -$740,519 | -$1.02M | -$1.52M |
| EPS (basic) | -0.17 | -0.43 | -0.43 | — | -0.37 | -1.33 | -1.92 | — |
| EPS (diluted) | -0.17 | -0.43 | -0.43 | — | -0.37 | -1.33 | -1.92 | — |
| Weighted avg. shares (diluted) | 3.74M | 1.80M | 1.80M | — | 1.80M | 557,787 | 530,618 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.09M | $4.03M | $4.53M | $5.33M | $6.05M | $6.64M | $2.75M | $3.33M |
| Current assets | $6.43M | $4.44M | $4.98M | $5.80M | $6.35M | $7.00M | $3.16M | $3.86M |
| Total assets | $6.43M | $4.44M | $4.98M | $5.80M | $6.35M | $7.00M | $3.16M | $3.86M |
| Current liabilities | $480,775 | $512,018 | $309,386 | $418,587 | $334,282 | $406,142 | $251,158 | $377,712 |
| Total liabilities | $480,775 | $512,018 | $309,386 | $418,587 | $334,282 | $406,142 | $251,158 | $377,712 |
| Shareholders' equity | $5.95M | $3.92M | $4.67M | $5.38M | $6.02M | $6.60M | $2.91M | $3.48M |
| Shares outstanding | 3.39M | 1.81M | 1.80M | 1.80M | 1.80M | 1.69M | 3.27M | 492,417 |
| Cash flow statement | ||||||||
| Operating cash flow | -$532,275 | -$518,440 | -$804,282 | -$714,762 | -$591,384 | -$458,879 | -$926,125 | -$1.35M |
| Financing cash flow | $2.59M | — | — | $0 | $0 | $4.35M | $347,549 | $1.11M |
| Stock-based compensation | $3,425 | $8,253 | $23,505 | $45,674 | $87,180 | $72,899 | $50,605 | $100,754 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.